journal article·2024-08Open access

Endothelial dysfunction and cardiovascular diseases: The role of human induced pluripotent stem cells and tissue engineering

Mary H. C. Florido, Nicholas P. Ziats

Abstract

Abstract Cardiovascular disease (CVD) remains to be the leading cause of death globally today and therefore the need for the development of novel therapies has become increasingly important in the cardiovascular field. The mechanism(s) behind the pathophysiology of CVD have been laboriously investigated in both stem cell and bioengineering laboratories. Scientific breakthroughs have paved the way to better mimic cell types of interest in recent years, with the ability to generate any cell type from reprogrammed human pluripotent stem cells. Mimicking the native extracellular matrix using both organic and inorganic biomaterials has allowed full organs to be recapitulated in vitro. In this paper, we will review techniques from both stem cell biology and bioengineering which have been fruitfully combined and have fueled advances in the cardiovascular disease field. We will provide a brief introduction to CVD, reviewing some of the recent studies as related to the role of endothelial cells and endothelial cell dysfunction. Recent advances and the techniques widely used in both bioengineering and stem cell biology will be discussed, providing a broad overview of the collaboration between these two fields and their overall impact on tissue engineering in the cardiovascular devices and implications for treatment of cardiovascular disease.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pluripotent Stem Cells Research · Tissue Engineering and Regenerative Medicine · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology Case Western Reserve University Cleveland Ohio USA

Harvard T.H. Chan School of Public Health, Harvard University Boston Massachusetts USA

Harvard Department of Stem Cell and Regenerative Biology Harvard University Cambridge Massachusetts USA

Departments of Biomedical Engineering and Anatomy Case Western Reserve University Cleveland Ohio USA

References (100+)

Show source-provided references
1. Heart disease and stroke statistics—2023 update: a report from the American Heart Association
3. Endothelial function: cardiac events10.1161/01.CIR.0000153339.27064.14 ↗
4. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms10.1161/01.RES.0000255691.76142.4a ↗
5. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress10.1161/01.RES.87.10.840 ↗
6. Tissue engineering approaches to uncover therapeutic targets for endothelial dysfunction in pathological environments10.3390/ijms23137416 ↗
7. Laubichler MD · 2007 · 5
8. Endothelial cells. Not just a cellophane wrapper10.1001/archinte.1987.00370030173034 ↗
9. Functional heterogeneity of vascular endothelial cells10.1016/0006-2952(87)90252-8 ↗
10. Félétou M · 2011
11. Endothelial function and dysfunction: testing and clinical relevance10.1161/CIRCULATIONAHA.106.652859 ↗
12. Role of endothelial dysfunction in atherosclerosis
13. Endothelial cell functions10.1002/jcp.10333 ↗
14. Ziats NP · 1989 · 289
15. The endothelial cell10.1136/bmj.2.5512.487 ↗
16. Endothelial function and dysfunction10.1097/00004872-200501000-00004 ↗
17. Endothelial dysfunction — a major mediator of diabetic vascular disease10.1016/j.bbadis.2013.08.006 ↗
18. Endothelial dysfunction and cardiovascular disease10.1159/000073580 ↗
19. Endothelial cell migration during angiogenesis10.1161/01.RES.0000259593.07661.1e ↗
20. Endothelial cell dysfunction and the pathobiology of atherosclerosis10.1161/CIRCRESAHA.115.306301 ↗
21. Endothelial dysfunction: a marker of atherosclerotic risk10.1161/01.ATV.0000051384.43104.FC ↗
22. Heterogeneity in endothelial cells from large vessels and microvessels10.1111/j.1432-0436.1987.tb00181.x ↗
23. Phenotypic heterogeneity is an evolutionarily conserved feature of the endothelium10.1182/blood-2006-05-026401 ↗
24. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force10.1161/01.ATV.18.5.677 ↗
25. Vascular endothelial cell development and diversity10.1038/s41569-022-00770-1 ↗
26. Testing endothelial function and its clinical relevance10.5551/jat.14340 ↗
27. Recruitment of immune cells into inflamed tissues: consequences for endothelial barrier integrity and tissue functionality10.1155/2016/1561368 ↗
28. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer10.1593/neo.05592 ↗
29. The endothelium, part I: multiple functions of the endothelial cells—focus on endothelium‐derived vasoactive mediators
30. Endothelium and its alterations in cardiovascular diseases: life style intervention10.1155/2014/801896 ↗
31. Systemic nature of endothelial dysfunction in atherosclerosis10.1016/0002-9149(95)80017-M ↗
32. Endothelial dysfunction: a marker of atherosclerotic risk10.1161/01.ATV.0000051384.43104.FC ↗
33. Endothelial dysfunction: a multifaceted disorder (the Wiggers award lecture). AJP: heart and circulatory
34. Endothelial dysfunction as a target for prevention of cardiovascular disease10.2337/dc09-S330 ↗
35. Endothelial dysfunction: does it matter? Is it reversible?10.1016/S0735-1097(97)00189-7 ↗
36. Long‐term follow‐up of patients with mild coronary artery disease and endothelial dysfunction10.1161/01.CIR.101.9.948 ↗
37. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology10.1038/ncpcardio1397 ↗
38. Endothelial dysfunction and cardiovascular risk factors10.1016/j.diabres.2008.12.013 ↗
39. Shear stress biology of the endothelium10.1007/s10439-005-8774-0 ↗
40. Quantitative measurement of shear‐stress effects on endothelial cells
41. Tissue engineering the vasculature tree10.1089/ten.teb.2017.0010 ↗
42. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells10.1038/ncb3205 ↗
43. Endothelial dysfunction10.1097/01.ASN.0000132474.50966.DA ↗
44. Go with the flow10.1161/01.CIR.103.23.2773 ↗
45. Risk factors in the development of coronary heart disease. Six year follow‐up experience—the Framingham study10.7326/0003-4819-54-5-1035_1 ↗
46. Beyond established and novel risk factors: lifestyle risk factors for cardiovascular disease10.1161/CIRCULATIONAHA.107.738732 ↗
47. Risk factors for cardiovascular disease and the Framingham study equation
48. Cardiovascular disease risk factors.World Heart Federation [Internet] [cited 2016 Jun 15]. Available from:http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/
49. AB0030 the LP13.3 genomic region ‘RS599839’ is associated with endothelial dysfunction in patients with rheumatoid arthritis10.1136/annrheumdis-2012-eular.30 ↗
50. The impact of genome‐wide association studies on the pathophysiology and therapy of cardiovascular disease10.15252/emmm.201506174 ↗
51. Genomewide association studies in cardiovascular disease—an update 201110.1373/clinchem.2011.170431 ↗
52. The Framingham heart study 100K SNP genome‐wide association study resource: overview of 17 phenotype working group reports10.1186/1471-2350-8-S1-S1 ↗
53. A genome‐wide association study of a coronary artery disease risk variant10.1038/jhg.2012.124 ↗
54. The assessment of endothelial function: from research into clinical practice10.1161/CIRCULATIONAHA.112.093245 ↗
55. Endothelial function testing as a biomarker of vascular disease10.1161/01.CIR.0000089191.72957.ED ↗
56. Endothelial dysfunction in endocrine disease10.1016/S1043-2760(01)00425-8 ↗
57. Endothelial function testing and cardiovascular disease: focus on peripheral arterial tonometry
58. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule10.1161/01.CIR.0000089507.19675.F9 ↗
59. Initial sequencing and comparative analysis of the mouse genome10.1038/nature01262 ↗
60. Strachan T · 1997
61. Extrapolation from mouse to man10.1161/CIRCIMAGING.110.961979 ↗
62. Technical challenges in using human induced pluripotent stem cells to model disease10.1016/j.stem.2009.11.009 ↗
63. Embryonic stem cell lines derived from human blastocysts10.1126/science.282.5391.1145 ↗
64. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro10.1038/74447 ↗
65. Derivation of embryonic stem‐cell lines from human blastocysts10.1056/NEJMsr040330 ↗
66. Derivation of human embryonic stem cell lines from embryos obtained after IVF and after PGD for monogenic disorders10.1093/humrep/dei345 ↗
67. Generation of a human embryonic stem cell line encoding the cystic fibrosis mutation ΔF508, using preimplantation genetic diagnosis10.1016/S1472-6483(10)61801-9 ↗
68. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos10.1016/j.stem.2007.09.001 ↗
69. Derivation of human embryonic stem cell line from preimplantation genetic diagnosed (PGD) fragile X‐affected embryos for the study of fragile X syndrome10.1016/j.fertnstert.2005.07.257 ↗
70. Cell biology: New potential for human embryonic stem cells10.1126/science.282.5391.1061 ↗
71. Stem cell technologies 1998–2008: controversies and cilences10.1080/09505430802514851 ↗
72. The endless hESC controversy in the United States: history, context, and prospects10.1016/j.stem.2010.10.008 ↗
73. Induction of pluripotent stem cells from adult human fibroblasts by defined factors10.1016/j.cell.2007.11.019 ↗
74. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors10.1016/j.cell.2006.07.024 ↗
75. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell‐based regeneration10.1161/CIRCULATIONAHA.109.881433 ↗
76. Reprogramming of human somatic cells to pluripotency with defined factors10.1038/nature06534 ↗
77. 10.1038/nrd357710.1038/nrd3577 ↗
78. Profile of John Gurdon and Shinya Yamanaka, 2012 Nobel laureates in medicine or physiology10.1073/pnas.1221823110 ↗
79. Endothelial dysfunction: role in obesity‐related disorders and the early origins of CVD10.1079/PNS2004404 ↗
80. Obesity and endothelial dysfunction10.1055/s-2005-871742 ↗
81. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion10.1016/j.cardiores.2006.03.013 ↗
82. Endothelial dysfunction and enhanced contractility in microvessels from ovariectomized rats: roles of oxidative stress and perivascular adipose tissue10.1161/HYPERTENSIONAHA.113.02284 ↗
83. Forkhead box O‐1 modulation improves endothelial insulin resistance in human obesity10.1161/ATVBAHA.114.305139 ↗
84. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET‐1 production10.1152/ajpheart.00092.2005 ↗
85. Role of insulin resistance in endothelial dysfunction10.1007/s11154-012-9229-1 ↗
86. Rapid and body weight‐independent improvement of endothelial and high‐density lipoprotein function after roux‐en‐Y gastric bypass: role of glucagon‐like peptide‐110.1161/CIRCULATIONAHA.114.011791 ↗
87. 10.1002/mnfr.20150093010.1002/mnfr.201500930 ↗
88. Association of non‐alcoholic fatty liver disease with impaired endothelial function by flow‐mediated dilation: a meta‐analysis
89. Nonalcoholic fatty liver disease and vascular function: cross‐sectional analysis in the Framingham heart study10.1161/ATVBAHA.114.305200 ↗
90. Posttraumatic stress disorder is associated with worse endothelial function among veterans10.1161/JAHA.115.003010 ↗
91. 10.1111/apha.1264610.1111/apha.12646 ↗
92. Endothelial dysfunction in hypertension10.2143/AC.55.4.2005744 ↗
93. Association of lower habitual physical activity level with mitochondrial and endothelial dysfunction in patients with stable coronary artery disease10.1253/circj.CJ-12-0364 ↗
94. Increased serum level of soluble vascular endothelial growth factor receptor‐1 is associated with poor coronary collateralization in patients with stable coronary artery disease10.1253/circj.CJ-13-1143 ↗
95. Concomitant impairment in endothelial function and neural cardiovascular regulation in offspring of type 2 diabetic subjects10.1161/01.HYP.0000234648.62994.ab ↗
96. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus10.1002/(SICI)1096-9136(199808)15:8<634::AID-DIA636>3.0.CO;2-8 ↗
97. Diabetes and endothelial dysfunction: a clinical perspective10.1210/edrv.22.1.0417 ↗
98. Diabetes mellitus and diabetes‐associated vascular disease10.1016/S1043-2760(01)00391-5 ↗
99. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease10.1002/(SICI)1520-7560(199911/12)15:6<405::AID-DMRR69>3.0.CO;2-H ↗
100. Mechanisms of endothelial dysfunction induced by aging: role of arginase I10.1161/CIRCRESAHA.107.162701 ↗